Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

Please always quote using this URN: urn:nbn:de:bvb:20-opus-236235
  • We report on a currently 76-year-old female patient with relapsed/refractory (RR) multiple myeloma (MM) treated at our institution. This patient had received six lines of therapy including tandem autologous stem cell transplant, proteasome inhibitor, immunomodulatory drugs and CD38 antibody MOR202. At the last relapse, she progressed during treatment with pomalidomide and MOR202. In an individualized therapy concept, we started a multi-agent salvage therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and CD38 antibody daratumumabWe report on a currently 76-year-old female patient with relapsed/refractory (RR) multiple myeloma (MM) treated at our institution. This patient had received six lines of therapy including tandem autologous stem cell transplant, proteasome inhibitor, immunomodulatory drugs and CD38 antibody MOR202. At the last relapse, she progressed during treatment with pomalidomide and MOR202. In an individualized therapy concept, we started a multi-agent salvage therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and CD38 antibody daratumumab (“Pom-PAD-Dara”), which resulted in a stringent complete remission with minimal residual disease (MRD) negativity after nine cycles. So far, our patient shows a progression free survival of more than 12 months. Our case demonstrates the feasibility of successful CD38 antibody retreatment in a patient with heavily pretreated CD38 antibody resistant MM.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Maximilian Johannes Steinhardt, Xiang Zhou, Franziska Krummenast, Katharina Meckel, Katharina Nickel, David Böckle, Janin Messerschmidt, Sebastian Knorz, Alexander Dierks, Anke Heidemeier, Constantin Lapa, Hermann Einsele, Leo Rasche, Klaus Martin Kortüm
URN:urn:nbn:de:bvb:20-opus-236235
Document Type:Journal article
Faculties:Medizinische Fakultät / Klinik und Poliklinik für Nuklearmedizin
Medizinische Fakultät / Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik)
Medizinische Fakultät / Medizinische Klinik und Poliklinik II
Language:English
Parent Title (English):International Journal of Immunopathology and Pharmacology
Year of Completion:2020
Volume:34
Pagenumber:1-5
Source:International Journal of Immunopathology and Pharmacology 2020, 34: 1–5. DOI: 10.1177/2058738420980258
DOI:https://doi.org/10.1177/2058738420980258
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Tag:CD38; MOR202; daratumumab; multiple myeloma; refractory; relapse
Release Date:2021/05/11
Collections:Open-Access-Publikationsfonds / Förderzeitraum 2020
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International